Boothbay Fund Management LLC Buys Shares of 1,237,057 CytomX Therapeutics, Inc. $CTMX

Boothbay Fund Management LLC purchased a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 1,237,057 shares of the biotechnology company’s stock, valued at approximately $3,946,000. Boothbay Fund Management LLC owned 0.73% of CytomX Therapeutics as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of CTMX. Ameriprise Financial Inc. bought a new position in CytomX Therapeutics during the third quarter worth $505,000. Raymond James Financial Inc. boosted its holdings in CytomX Therapeutics by 3.5% in the 3rd quarter. Raymond James Financial Inc. now owns 293,560 shares of the biotechnology company’s stock valued at $936,000 after purchasing an additional 10,000 shares during the period. ADAR1 Capital Management LLC boosted its holdings in CytomX Therapeutics by 31.3% in the 3rd quarter. ADAR1 Capital Management LLC now owns 4,045,414 shares of the biotechnology company’s stock valued at $12,905,000 after purchasing an additional 964,000 shares during the period. Brooklyn Investment Group acquired a new stake in CytomX Therapeutics in the 3rd quarter worth $278,000. Finally, Two Sigma Investments LP increased its holdings in shares of CytomX Therapeutics by 362.8% during the 3rd quarter. Two Sigma Investments LP now owns 729,698 shares of the biotechnology company’s stock worth $2,328,000 after purchasing an additional 572,017 shares during the period. 67.77% of the stock is owned by institutional investors.

Trending Headlines about CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 expansion data show solid activity in late‑line colorectal cancer — confirmed response rates of 32% at 10 mg/kg Q3W and 20% at 8.6 mg/kg Q3W, estimated PFS ~7.1 months at the higher dose, and manageable safety with ongoing dose optimization. Management is targeting mid‑year FDA interactions to align on a potential registrational trial. Varsetatug Masetecan Continues to Demonstrate Positive Data
• Positive Sentiment: Analyst upgrades and higher price targets lifted sentiment — HC Wainwright raised its target to $17 (buy) and JPMorgan upgraded CTMX to overweight with a $12 target; Seeking Alpha and Benzinga published bullish takes tying valuation to Varseta‑M’s late‑line mCRC opportunity. These notes reinforced upside expectations. Mid‑Cap CytomX Therapeutics’ Colorectal Cancer Data Fuels Stock Rally
• Neutral Sentiment: Market reaction and high trading volume: CTMX experienced unusually heavy volume and a large pre‑market move as headlines circulated and investors digested the clinical readout plus analyst commentary. That amplifies intraday volatility but is informational rather than fundamental by itself. Why CTMX Stock Is Soaring Pre‑Market
• Negative Sentiment: Proposed $250M underwritten public offering of common stock and pre‑funded warrants — the financing will be dilutive and typically weighs on near‑term per‑share metrics despite extending the cash runway for development. CytomX Announces Proposed Public Offering
• Negative Sentiment: Q4 miss on EPS and revenue — CTMX reported a ($0.22) EPS vs. consensus (~$0.08 loss) and revenue well below estimates, reinforcing near‑term cash burn and highlighting the company remains pre‑commercial. These fundamentals contrast with the positive clinical news. CTMX Reports Q4 Loss, Misses Revenue Estimates

Analysts Set New Price Targets

A number of brokerages have recently commented on CTMX. Guggenheim reaffirmed a “buy” rating and set a $10.00 price objective on shares of CytomX Therapeutics in a research report on Monday, March 9th. Oppenheimer restated an “outperform” rating and set a $12.00 price target on shares of CytomX Therapeutics in a research note on Monday. Piper Sandler upped their price target on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. JPMorgan Chase & Co. upgraded CytomX Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $7.00 to $12.00 in a research report on Monday. Finally, Barclays lifted their price objective on CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, CytomX Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $10.88.

CytomX Therapeutics Trading Up 44.2%

Shares of CytomX Therapeutics stock opened at $6.75 on Tuesday. The firm’s 50-day moving average price is $5.24 and its two-hundred day moving average price is $4.07. CytomX Therapeutics, Inc. has a 1-year low of $0.40 and a 1-year high of $8.21. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of 16.88 and a beta of 2.44.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.